Aug. 23, 2018
A vaccine approach to target ANGPTL3 for reducing triglycerides in order to prevent cardiovascular diseases and other diseases that are associated with hypertriglyceridemia.
Using a virus-like particle (VLP) based vaccine platform, this vaccine can induce strong antibody responses against ANGPTL3 and reduce triglyceride levels in animal models.
Triglycerides (TGs) are a type of fat found in the blood. Elevated serum triglycerides are a major risk factor for atherosclerosis, the narrowing of arteries with the buildup of fatty plaques that may lead to heart attack, stroke, peripheral artery disease and other cardiovascular conditions. Plasma TGs are metabolized by the enzyme lipoprotein lipase (LPL), which catalyzes the hydrolysis of TGs into free fatty acids, which are either re-esterified for storage or oxidized for fuel. The secreted protein angiopoietin-like 3 (ANGPTL3) and its relatives regulate LPL activity by binding and inactivating this enzyme. Inhibition of ANGPTL3 can dramatically reduce TG levels.
Researchers at the University of New Mexico and the National Institutes of Health (NIH) have developed a vaccine approach to target ANGPTL3 for reducing triglycerides in order to prevent cardiovascular diseases and other diseases that are associated with hypertriglyceridemia. Using a virus-like particle (VLP) based vaccine platform, this vaccine can induce strong antibody responses against ANGPTL3 and reduce triglyceride levels in animal models.
由于技术保密工作限制，技术信息无法完全展现，请通过邮箱或短信联系我们，获取更多技术资料。
reduce triglyceride levels
major risk factor
peripheral artery disease
technology description researchers
free fatty acids
B5, No.1600, North Guoquan Rd, Yangpu, Shanghai
info@yintrust.com
021-65679356
Premium